In this study, we demonstrated that PIK3CA mutations, which lead to constitutive activation of the PI3K/AKT/mTOR pathway, play important roles in resistance against HER2 monotherapy in breast cancer cell lines. The gene discussed is PIK3CA; the disease is breast carcinoma.